This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties
This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Subscribe To Our Newsletter & Stay Updated
